High-affinity human PD-L1 variants attenuate the suppression of T cell activation.

The activated T cells can be suppressed by programed death-1 (PD-1) axis through low affinity interaction between PD-1 and PD-ligand 1 (PD-L1) in solution or on antigen presenting cells. In clinic， the concentration of soluble PD-L1 in peripheral blood negatively correlates with cancer prognosis. However， there is little information about the relation between the affinity of PD-1/PD-L1 interaction and the suppressive capacity of PD-1 axis. In this study， we analyzed inhibitory roles of high affinity soluble human PD-L1 (hPD-L1) variants， which were generated with directed molecular evolution. Resultant two clones L3C7-hPD-L1 and L3B3-hPD-L1 showed over 20 folds greater affinity than that of native hPD-L1. We found that L3B3-hPD-L1 and L3C7-hPD-L1 could compete with an anti-PD-1 antibody (EH12.1) for binding to hPD-1. More importantly， although native soluble hPD-L1 can induce suppressive effects on activated T cells， we found L3B3-hPD-L1 and L3C7-hPD-L1 attenuated the strength of PD-1 axis for suppressing the proliferation and interferon γ (IFN-γ) secretion of PBMC. In conclusion， our data provide direct evidence in which immune checkpoint receptor-ligand interactive strength can alter the the suppressive function， in particular， the suppressive capacity of PD-1 axis could be decreased with enhanced affinity of soluble PD-L1 and PD-1 interaction. Our study might provide a new direction for manipulating immune checkpoints.